Q-Line Biotech SME IPO Gears Up: Today’s GMP and Pricing Insights Revealed!

The Q-Line Biotech SME IPO is set to open for subscription on May 21, 2026, with a primary objective of raising approximately ₹251 crore. The shares are being offered in a price band of ₹326 to ₹343 per share, and the minimum investment requires a market lot of 400 shares. The response to the IPO is expected to be robust as investors gauge the overall market sentiment and evaluate the company’s fundamentals ahead of the listing date.

Currently, the grey market sentiment shows a healthy interest in the Q-Line Biotech IPO, with the Grey Market Premium (GMP) standing at ₹69. This indicates positive anticipation among investors about the stock’s performance post-listing. Moreover, the Kostak rate is quoted at ₹800+, reflecting an optimistic outlook. The day-wise GMP trend reveals that the IPO experienced a high of ₹69 on May 19, 2026, and a low of ₹42 on May 18, suggesting fluctuating yet encouraging investor sentiment leading up to the issue’s opening.

For Indian investors, the Q-Line Biotech IPO presents a potential opportunity to participate in the SME segment of the market, which has been gaining traction. The strong grey market indicators suggest that there could be substantial demand for the shares upon listing, making this IPO an attractive consideration for investors seeking to diversify their portfolios. Continuous monitoring of subscription data and grey market trends will be crucial for making informed investment decisions as the opening date approaches.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)